These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 12719582

  • 1. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    Pantophlet R, Wilson IA, Burton DR.
    J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
    [Abstract] [Full Text] [Related]

  • 2. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
    Pantophlet R, Wilson IA, Burton DR.
    Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
    [Abstract] [Full Text] [Related]

  • 3. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [Abstract] [Full Text] [Related]

  • 4. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
    Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR.
    J Virol; 2003 Jan; 77(1):642-58. PubMed ID: 12477867
    [Abstract] [Full Text] [Related]

  • 5. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, Burton DR.
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [Abstract] [Full Text] [Related]

  • 6. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.
    Varadarajan R, Sharma D, Chakraborty K, Patel M, Citron M, Sinha P, Yadav R, Rashid U, Kennedy S, Eckert D, Geleziunas R, Bramhill D, Schleif W, Liang X, Shiver J.
    J Virol; 2005 Feb; 79(3):1713-23. PubMed ID: 15650196
    [Abstract] [Full Text] [Related]

  • 7. Comparing antigenicity and immunogenicity of engineered gp120.
    Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR.
    J Virol; 2005 Oct; 79(19):12148-63. PubMed ID: 16160142
    [Abstract] [Full Text] [Related]

  • 8. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV, Parren PW, Burton DR.
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [Abstract] [Full Text] [Related]

  • 9. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.
    PLoS One; 2018 Jun; 13(4):e0194266. PubMed ID: 29698406
    [Abstract] [Full Text] [Related]

  • 10. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
    Sterjovski J, Churchill MJ, Ellett A, Wesselingh SL, Ramsland PA, Gorry PR.
    Virology; 2012 Oct 25; 432(2):394-404. PubMed ID: 22818780
    [Abstract] [Full Text] [Related]

  • 11. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S, Li Y, Kozyrev Y, Cleveland B, Hu SL.
    J Virol; 2016 Jan 15; 90(2):829-41. PubMed ID: 26512079
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 18. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding.
    Berkower I, Patel C, Ni Y, Virnik K, Xiang Z, Spadaccini A.
    Virology; 2008 Aug 01; 377(2):330-8. PubMed ID: 18519142
    [Abstract] [Full Text] [Related]

  • 19. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA.
    Science; 2001 Aug 10; 293(5532):1155-9. PubMed ID: 11498595
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.